In this context, the discovery of FGFR3::TACC3 fusion in a subset of tumors previously classified as glioblastoma [30] has prompted physicians to better characterize this group and to explore the therapeutic efficacy of FGFR inhibitors in patients with glioma harboring FGFR3:TACC3 chromosomal translocation [13–15, 22, 31]. This evidence concerns the gene TACC3 and glioblastoma.